MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma.
Pratik TalatiMohamed El-AbtahDaniel KimJorg DietrichMelanie FuMichael WenkeJulian HeSharif N NatheirMark VangelOtto RapalinoAnna VaynrubIsabel Arrillaga-RomanyDeborah A ForstYi-Fen YenOvidiu AndronesiJayashree Kalpathy-CramerBruce RosenTracy T BatchelorR Gilberto GonzalezElizabeth R GerstnerEva-Maria RataiPublished in: Neuro-oncology advances (2021)
Changes in metabolic levels of tumoral NAA/Cho and Lac/NAA can serve as early biomarkers for predicting treatment failure to anti-angiogenic therapy as soon as 1 day after bevacizumab-based therapy. The addition of MRS to conventional MR methods can provide better insight into how anti-angiogenic therapy affects tumor microenvironment and predict patient outcomes.